Transcatheter tricuspid valve replacement (TTVR) is a minimally invasive, catheter-based procedure used to treat severe tricuspid regurgitation, a condition in which the tricuspid valve does not close properly, allowing blood to leak backward from the right ventricle into the right atrium. The procedure implants a new bioprosthetic, or tissue, valve within the diseased native valve to take over its function without conventional open-heart surgery.

​

Careful patient selection and pre-procedural imaging are essential. The primary goals of TTVR are to reduce tricuspid regurgitation, relieve symptoms such as fatigue and shortness of breath, and improve functional capacity and quality of life. These benefits depend on appropriate patient selection and the individual’s underlying cardiac condition.

​

Following treatment, patients require individualized antithrombotic therapy, including anticoagulation as prescribed, to reduce the risk of clot formation on the implanted valve. Ongoing cardiology follow-up and echocardiographic assessment help evaluate valve function, residual leakage, and recovery. Continued management of associated heart failure remains an important part of long-term care.